FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Regeneron Pharmaceuticals Inc patents


      
Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors


Human lambda light chain mice

Regeneron Pharmaceuticals

Human lambda light chain mice

Search recent Press Releases: Regeneron Pharmaceuticals Inc-related press releases
Count Application # Date Regeneron Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
12015017333106/25/15Human lambda light chain mice
22015017333206/25/15Human lambda light chain mice
32015017567606/25/15Fusion polypeptides capable of activating receptors
42015017568806/25/15Production cell line enhancers
52015017600206/25/15Human lambda light chain mice
62015016559806/18/15Devices and methods for facilitating treatment of electrospray columns
72015016664706/18/15Antikine antibodies that bind to multiple cc chemokines
82015016021506/11/15Isolating cells expressing secreted proteins
92015015217706/04/15High affinity human antibodies to human angiopoietin-2
102015015219106/04/15Dosing regimens for use with pcsk9 inhibitors
112015014734205/28/15Methods for treating cancer by administering an anti-ang-2 antibody
122015014000205/21/15Use of a pcsk9 inhibitor to treat hyperlipidemia
132015014355805/21/15Non-human animals having a humanized b-cell activating factor gene
142015014355905/21/15Non-human animals having a humanized a proliferation-inducing ligand gene
152015014356105/21/15Non-human animals having a humanized b-cell activating factor gene
162015014356205/21/15Non-human animals having a humanized a proliferation-inducing ligand gene
172015011955604/30/15Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
182015011075404/23/15High resolution allele identification
192015011080104/23/15Human antibodies to gfr alpha 3 and methods of use thereof
202015010573504/16/15Syringe pistons, systems and methods
212015010696104/16/15Humanized il-15 animals
222015009929604/09/15Promoter-regulated differentiation-dependent self-deleting cassette
232015010003004/09/15Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
242015008967803/26/15Non-human animals having a humanized signal-regulatory protein gene
252015008967903/26/15Non-human animals having a humanized signal-regulatory protein gene
262015008968003/26/15Human lambda light chain mice
272015007908703/19/15Vegf antagonist formulations
282015008246903/19/15Humanized il-7 rodents
292015006418903/05/15Method of treating cancer with dll4 antagonist and chemotherapeutic agent
302015006790103/05/15Production of fertile xy female animals from xy es cells
312015005622102/26/15Anti-prlr antibodies and uses thereof
322015005622202/26/15Anti-prlr antibodies and uses thereof
332015005900902/26/15Methods for making fully human bispecific antibodies using a common light chain
342015004706102/12/15Humanized m-csf mice
352015004706202/12/15Lincrna-deficient non-human animals
362015003733902/05/15Anti-activin a antibodies and uses thereof
372015004025302/05/15Genetically modified major histocompatibility complex mice
382015002441201/22/15Humanized fcgammar mice
392015001717601/15/15Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
402015001718201/15/15Methods for treating nasal polyposis by administering an il-4r antagonist
412015002022401/15/15Non-human animals with modified immunoglobulin heavy chain sequences
422015001056801/08/15Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
432015001302201/08/15Humanized il-6 and il-6 receptor
442015001302301/08/15Humanized il-6 and il-6 receptor
452014035637012/04/14Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
462014035637112/04/14Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
472014035637212/04/14Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
482014033134011/06/14Methods and compositions for generating a mouse
492014032221510/30/14Methods of inhibiting tumor growth by antagonizing il-6 receptor
502014031524910/23/14Inducible eukaryotic expression system
512014028987609/25/14Mice that make heavy chain antibodies
522014027164209/18/14Il-33 antagonists and uses thereof
532014027165309/18/14Human antibodies to respiratory syncytial virus f protein and methods of use thereof
542014027165809/18/14Anti-il-33 antibodies and uses thereof
552014027168109/18/14High affinity human antibodies to human il-4 receptor
562014027309509/18/14Serum-free cell culture medium
572014027548909/18/14Apelin fusion proteins and uses thereof
582014028315809/18/14Rodents with conditional acvr1 mutant alleles
592014025539009/11/14Method of treating rheumatoid arthritis with an anti-il-6r antibody
602014025541909/11/14Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
612014025542909/11/14Methods of treating autoimmune diseases with dll4 antagonists
622014025599509/11/14High affinity antibodies to human il-6 receptor
632014024866409/04/14Readily isolated bispecific antibodies with native immunoglobulin format
642014024350408/28/14Antibodies comprising chimeric constant domains
652014024546608/28/14Humanized t cell co-receptor mice
662014024546708/28/14Genetically modified major histocompatibility complex mice
672014024546808/28/14Non-human animals with modified immunoglobulin heavy chain sequences
682014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
692014021377307/31/14Adam6 mice
702014019655007/17/14Systems and devices for sample handling
712014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
722014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
732014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
742014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
752014017887906/26/14Compositions and methods for modifying cells
762014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
772014015470106/05/14Humanized fc gamma r mice
782014015568906/05/14Methods of modifying genes in eukaryotic cells
792014015744506/05/14Low affinity fcgr deficient mice
802014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
812014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
822014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
832014013471905/15/14Recombinant cell surface capture proteins
842014013727505/15/14Hybrid light chain mice
852014013019305/08/14Mice that make vl binding proteins
862014013019405/08/14Mice that make vl binding proteins
872014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
882014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
892014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
902014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
912014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
922014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
932014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
942014007297903/13/14Isolating cells expressing secreted proteins
952014007298003/13/14Isolating cells expressing secreted proteins
962014007301003/13/14Methods of modifying eukaryotic cells
972014007558603/13/14Parental cell lines for making cassette-free f1 progeny
982014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
992014005690702/27/14Anti-asic1 antibodies and uses thereof
1002014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
1012014004106802/06/14Methods of modifying eukaryotic cells
1022014003333601/30/14Methods of modifying eukaryotic cells
1032014003333701/30/14Methods of modifying eukaryotic cells
1042014002363701/23/14Methods of modifying eukaryotic cells
1052014001722801/16/14Humanized light chain mice
1062014001722901/16/14Methods of modifying eukaryotic cells
1072014001723801/16/14Methods of modifying eukaryotic cells
1082014001769501/16/14Isolating cells expressing secreted proteins
1092014001778101/16/14Methods of modifying eukaryotic cells
1102014001778201/16/14Methods for modifying eukaryotic cells
1112014001852201/16/14Methods of modifying eukaryotic cells
1122014002012401/16/14Methods of modifying eukaryotic cells
1132014002012501/16/14Methods of modifying eukaryotic cells
1142014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1152014001345701/09/14Methods of modifying eukaryotic cells
1162013034453812/26/13Human antibodies to the glucagon receptor
1172013034010412/19/13Humanized il-7 rodents
1182013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
1192013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
1202013032326112/05/13Purified antibody composition
1212013032378812/05/13Production cell line enhancers
1222013032379012/05/13Human lambda light chain mice
1232013032379112/05/13Restricted immunoglobulin heavy chain mice
1242013032664712/05/13Human lambda light chain mice
1252013030967011/21/13Nuclease-mediated targeting with large targeting vectors
1262013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
1272013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
1282013029509711/07/13Human antibodies to fel d1 and methods of use thereof
1292013028075810/24/13Fusion polypeptides capable of activating receptors
1302013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
1312013026657410/10/13Human antibodies to human angiopoietin-like protein 4
1322013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
1332013025988110/03/13Fusion polypeptides capable of activating receptors
1342013026105610/03/13Vegf antagonist formulations
1352013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1362013025491109/26/13Adam6 mice
1372013024377509/19/13Multispecific antigen-binding molecules and uses thereof
1382013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1392013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1402013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
1412013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
1422013023053109/05/13Human antibodies to clostridium difficile toxins
1432013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1442013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1452013020949208/15/13Anti-tie2 antibodies and uses thereof
1462013021013708/15/13Methods of modifying eukaryotic cells
1472013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1482013019587808/01/13Anti-asic1 antibodies and uses thereof
1492013019887908/01/13Humanized universal light chain mice
1502013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1512013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1522013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1532013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1542013018581907/18/13Genetically modified major histocompatibility complex animals
1552013018582007/18/13Genetically modified major histocompatibility complex animals
1562013018582107/18/13Common light chain mouse
1572013017114907/04/13Anti-angptl3 antibodies and uses thereof
1582013016478606/27/13Fucosylation-deficient cells
1592013015731306/20/13High affinity antibodies to human il-6 receptor
1602013016015306/20/13Humanized light chain mice
1612013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1622013013710105/30/13Methods of modifying eukaryotic cells
1632013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1642013012983005/23/13Polymer protein microparticles
1652013013037205/23/13Enhanced expression and stability regions
1662013013038805/23/13Methods of modifying eurakyotic cells
1672013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1682013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1692013011787305/09/13Humanized il-6 and il-6 receptor
1702013010905305/02/13Genetically modified t cell receptor mice
1712013011161605/02/13Genetically modified major histocompatibility complex mice
1722013011161705/02/13Genetically modified major histocompatibility complex mice
1732013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1742013009628704/18/13Restricted immunoglobulin heavy chain mice
1752013008429704/04/13Anti-erbb3 antibodies and uses thereof
1762013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1772013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1782013007867503/28/13High affinity human antibodies to human il-4 receptor
1792013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1802013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1812013003490202/07/13Fusion polypeptides capable of activating receptors
1822013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1832012032210812/20/12Adam6 mice
1842012032349712/20/12Non-hypergeometric overlap probability
1852012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1862012026035710/11/12Low affinity fcgr deficient mice
1872012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1882012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1892012019230007/26/12Common light chain mouse
1902012017868307/12/12Vegf antagonist formulations
1912012016468806/28/12High affinity human antibodies to human nerve growth factor
1922012013501005/31/12High affinity human antibodies to human il-4 receptor
1932012012867905/24/12Human antibodies to the glucagon receptor
1942012011464505/10/12Use of il-1 antagonists to treat pseudogout
1952012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1962012011466505/10/12Human antibodies to human rankl
1972012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1982012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1992012010103504/26/12Vegf antagonist formulations
2002012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
2012012009657204/19/12Mice that make vl binding proteins
2022012008792904/12/12Vegf antagonist formulations for intravitreal administration
2032012008300004/05/12Neuropeptide release assay for sodium channels
2042012007679003/29/12Anti-cd48 antibodies and uses thereof
2052012007086103/22/12Human lambda light chain mice
2062012007300403/22/12Hybrid light chain mice
2072012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
2082012005207203/01/12High affinity human antibodies to human il-4 receptor
2092012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
2102012002140901/26/12Common light chain mouse
2112012001496801/19/12Stabilized formulations containing anti-ngf antibodies
2122012000369701/05/12High affinity antibodies to human il-6 receptor
2132011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
2142011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
2152011030796612/15/11Mice expressing human voltage-gated sodium channels
2162011030796812/15/11Production of fertile xy animals from xy es cells
2172011029363012/01/11Antibodies to human gdf8
2182011028337611/17/11Methods of modifying eukaryotic cells
2192011026918711/03/11High affinity human antibodies to human il-18 receptor
2202011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
2212011025655610/20/11Humanized fcgr mice
2222011025658710/20/11High affinity human antibodies to human nerve growth factor
2232011025760110/20/11Vegf antagonist formulations for intravitreal administration
2242011025871010/20/11Methods of modifying eukaryotic cells
2252011019545408/11/11Common light chain mouse
2262011018917608/04/11Methods of treating diseases with dll4 antagonists
2272011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
2282011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2292011016565007/07/11Fusion polypeptides capable of activating receptors
2302011015901506/30/11Human antibodies to human angiopoietin-like protein 4
2312011015090506/23/11Human antibodies to human delta like ligand 4
2322011015451206/23/11Humanized fc gamma r mice
2332011014593706/16/11Mice that make heavy chain antibodies
2342011010479905/05/11Multifunctional alleles
2352011008168104/07/11Human antibodies to human cd20 and using thereof
2362011006590203/17/11High affinity human antibodies to pcsk9
2372011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2382011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2392011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2402011002728602/03/11High affinity human antibodies to human angiopoietin-2
2412011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2422011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2432011000837401/13/11Use of il-1 antagonists to treat gout
2442010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2452010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2462010031662712/16/10Human antibodies to human il-6 receptor
2472010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2482010030443612/02/10Fucosylation-deficient cells
2492010029110711/18/10High affinity human antibodies to human il-4 receptor



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE